Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Subscribe To Our Newsletter & Stay Updated